- •The predictive value of hs-CRP levels on cancer and all-cause mortality risk is conflicting.
- •Subjects with the highest hs-CRP levels increased by 75% the risk of all-cause mortality.
- •Subjects with the highest hs-CRP levels increased by 2.03-fold the risk of cardiovascular mortality.
- •Hs-CRP can stratify cardiovascular and all-cause mortality risk in the general population.
- •Gender-specific predictive value of hs-CRP on cancer mortality needs to be further investigated.
Background and aims
Inconsistent findings have been reported on the association between high-sensitivity C-reactive protein (hs-CRP) and mortality risk. The objective of this meta-analysis was to investigate the association of elevated baseline hs-CRP levels with all-cause, cardiovascular, and cancer mortality risk in the general population.
PubMed and Embase were systematically searched for studies published from inception to October 2016. Prospective observational studies were eligible if they reported the effects of elevated baseline hs-CRP levels on cancer-related, cardiovascular or all-cause mortality in the general population. The pooled adjusted risk ratio (RR) with 95% confidence interval (CI) comparing the highest to the lowest category of hs-CRP levels was used as association measures.
A total of 83,995 participants from 14 studies were identified. When comparing the highest to the lowest category of hs-CRP levels, the pooled RR was 1.25 (95% CI 1.13–1.38) for cancer-related mortality, 2.03 (95% CI 1.65–2.50) for cardiovascular mortality, and 1.75 (1.55–1.98) for all-cause mortality, respectively. Subgroup analysis showed that the effect of elevated hs-CRP levels on cancer-related mortality was observed in men (RR 1.26; 95% CI 1.11–1.43) but not in women (RR 1.03; 95% CI 0.83–1.27).
Elevated hs-CRP levels can independently predict risk of all-cause, cardiovascular mortality in the general population. However, the gender differences in the predictive role of hs-CRP on cancer mortality should to be further investigated.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- C-reactive protein: a critical update.J. Clin. Invest. 2003; 111: 1805-1812
- Inflammatory networks in ageing, age-related diseases and longevity.Mech. Ageing Dev. 2007; 128: 83-91
- Distribution of C-reactive protein values in the United States.N. Engl. J. Med. 2005; 352: 1611-1613
- C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study.Atherosclerosis. 2007; 195: e195-202
- A test in context: high-sensitivity C-Reactive protein.J. Am. Coll. Cardiol. 2016; 67: 712-723
- Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies.Asian Pac J. Cancer Prev. 2013; 14: 243-248
- C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study.Eur. Heart J. 2005; 26: 1783-1789
- Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein.Arch. Intern Med. 2008; 168: 200-206
- High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study.Arterioscler. Thromb. Vasc. Biol. 2008; 28: 1385-1391
- Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998.Clin. Chem. 2008; 54: 335-342
- Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population.Atherosclerosis. 2009; 204: 234-238
- High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study.Neurology. 2009; 73: 1300-1307
- Association of very highly elevated C-reactive protein concentration with cardiovascular events and all-cause mortality.Clin. Chem. 2010; 56: 132-135
- Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study.Eur. J. Epidemiol. 2013; 28: 541-550
- B-type natriuretic peptide, C-reactive protein, and cause-specific mortality.Ann. Epidemiol. 2013; 23: 66-73
- High sensitive C-reactive protein (hsCRP), cardiovascular events and mortality in the aged: a prospective 9-year follow-up study.Arch. Gerontol. Geriatr. 2015; 60: 112-117
- Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality: the hordaland health study.Am. J. Epidemiol. 2016; 183: 249-258
- High-sensitivity C-Reactive protein and risks of all-cause and cause-specific mortality in a japanese population.Asian Pac J. Cancer Prev. 2016; 17: 2643-2648
- Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer.J. Clin. Oncol. 2009; 27: 2217-2224
- Inflammatory biomarker score and cancer: a population-based prospective cohort study.BMC Cancer. 2016; 16: 80
- Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : jichi Medical School Cohort Study.Am. J. Epidemiol. 2001; 153: 1183-1190
- Ethnic differences in C-reactive protein concentrations.Clin. Chem. 2008; 54: 1027-1037
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.Lancet. 2010; 375: 132-140
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.Ann. Intern Med. 2009; 151 (W64): 264-269
- The Newcastle–Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-analyses.(Accessed 6 April 2014)
- Measuring inconsistency in meta-analyses.BMJ. 2003; 327: 557-560
- Operating characteristics of a rank correlation test for publication bias.Biometrics. 1994; 50: 1088-1101
- Bias in meta-analysis detected by a simple, graphical test.BMJ. 1997; 315: 629-634
- High-sensitivity C-reactive protein levels and cancer mortality.Cancer Epidemiol. Biomarkers Prev. 2012; 21: 2076-2086
- Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: the BioCycle Study.Am. J. Epidemiol. 2012; 175: 423-431
- Inflammation and immune system interactions in atherosclerosis.Cell Mol. Life Sci. 2013; 70: 3847-3869
- Inflammation and atherosclerosis: direct versus indirect mechanisms.Curr. Opin. Pharmacol. 2013; 13: 154-160
- High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.Int. J. Cardiol. 2013; 168: 5126-5134
- Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects.Arterioscler. Thromb. Vasc. Biol. 1997; 17: 2167-2176
- C-reactive protein and incident diabetes in patients with arterial disease.Eur. J. Clin. Invest. 2013; 43: 1052-1059
- C-reactive protein in hypertension: clinical significance and predictive value.Nutr. Metab. Cardiovasc Dis. 2006; 16: 500-508
- The Prospective Study of Association between C-reactive Protein and Hypertension in Community Population Zhonghua Yu Fang Yi Xue Za Zhi. vol. 47. 2013: 1026-1030
- Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.Z Kardiol. 2005; 94: 336-342
- Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review.Ann. Intern Med. 2003; 139: 670-682
- Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.Cardiovasc Diabetol. 2011; 10: 65
Published online: February 08, 2017
Accepted: February 7, 2017
Received in revised form: January 11, 2017
Received: December 2, 2016
© 2017 Elsevier B.V. All rights reserved.